An Integrated Multi-omics Study on the Molecular Mechanisms of Ureteral Stricture

Condition(s) studied

Study summary

The goal of this observational study is to investigate the systemic pathogenesis and identify potential diagnostic biomarkers in patients with ureteral stricture and healthy volunteers. The main questions it aims to answer are:

What are the systemic differences in the gut microbiome, urine microbiome, and metabolomic profiles (fecal, urinary, and serum) between patients with ureteral stricture and healthy controls? What are the correlations between these microbial/metabolic alterations and clinical phenotypes, such as stricture severity, inflammatory levels, and renal function? Researchers will compare the biological panoramic profiles of patients with ureteral stricture to those of healthy controls to see if specific "microbiome-metabolite-disease" regulatory networks drive the development of the condition.

Participants will:

Provide stool samples for gut microbiome (16S/Metagenomics) and metabolomic analysis.

Provide urine samples for urine microbiome and metabolomic analysis. Provide blood (serum) samples for systemic metabolomic profiling. Undergo clinical assessments, including medical history collection, imaging (e.g., CT/IVP), and laboratory tests (e.g., renal function, inflammatory markers) to evaluate disease severity.

Eligibility

Primary outcome measure(s)

• Differences in Gut and Urinary Microbiome Composition — Baseline (at the time of sample collection, within 1 week of enrollment)
  Comparison of microbial diversity and taxonomic composition between ureteral stricture patients and healthy controls. Metrics include Alpha-diversity (e.g., Shannon Index), Beta-diversity (e.g., PCoA based on Bray-Curtis distance), and relative abundance of specific microbial taxa from Phylum to Genus levels using 16S rRNA or metagenomic sequencing.
• Differential Metabolomic Profiles in Fecal, Urinary, and Serum Samples — Baseline (at the time of sample collection, within 1 week of enrollment)
  Identification of significantly different metabolites between the two groups. Parameters include the concentration and relative intensity of metabolites identified via LC-MS/MS or GC-MS. Significant metabolites will be screened based on Variable Importance in Projection (VIP) \> 1.0 and p-value \< 0.05 from multivariate and univariate statistical analyses.

Trial sites (1)

More First Affiliated Hospital of Chongqing Medical University trials in China

Other trials for the same condition